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We report a case of early bioprosthetic valve calcification in a 76 year-old woman who had received
supplementation with alfacalcidol, an analogue of vitamin D, for 3 years after her initial valve replacement.
She underwent aortic valve replacement at the age of 71 and subsequently complained of shortness of breath.
Ultrasonic cardiography revealed severe aortic stenosis and we performed a second aortic valve replacement with a
bioprosthesis. Histopathologic and x-ray examination showed calcification on the explanted valve. She had not
presented with any known risk for early bioprosthetic calcification, suggesting that vitamin D supplementation may
accelerate calcification of bioprosthetic valves.
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Durability of bioprosthetic valve is increasing because
valve tissue treatment and valve structure is improving
from day to day, and actuarial freedom from explants due
to valve deterioration at 20 years is reported as 81.5% in
patients older than 64 years [1]. However, there are some
papers of early bioprosthetic valve deterioration in the
older patients, and risk factors for early deterioration of
bioprosthesis were not completely uncovered yet [2,3]. It
is important to report possible risk to understand mechan-
ism of early valve deterioration. We here describe a case
of early bioprosthetic valve calcification with alfacalcidol
supplementation.Case
A 76 year-old women visited a hospital complaining of
shortness of breath on effort. She had undergone aortic
valve replacement (AVR) for aortic stenosis with a 21 mm
Carpentier-Edwards Perimount (CEP, model 2900, Edwards
Lifesciences, CA, USA) concomitant with coronary artery
bypass grafting at the age of 71, 5 years previously. Echocar-
diography (UCG) showed aortic stenosis with a maximum
pressure gradient of 66 mmHg and an aortic valve area
(AVA) of 0.80 cm2. Shortness of breath worsened and* Correspondence: ttakano-ths@umin.ac.jp
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reproduction in any medium, provided the ororthopnea appeared 2 months after her initial symptoms
started and 1 month after the initial UCG. She was admit-
ted to the hospital and given intravenous dobutamine for
congestive heart failure. UCG showed rapid progression of
aortic stenosis with a maximum pressure gradient of
110 mmHg, an AVA of 0.30 cm2, and a fractional shorten-
ing (FS) of 37%. She was transferred to our hospital for sur-
gery. She had been taking 1 μg/day of alfacalcidol for
3 years for osteoporosis, starting 2 years after the initial
AVR, and amlodipine and levothyroxine for hypertension
and hypothyroidism, respectively. She also had a history of
right breast cancer. Blood chemistry showed a corrected
serum calcium (serum Ca-Albumin + 4) concentration of
9.1 ± 0.7 mg/dl (with a range of 8.0 to 10.2 mg/dl) at the
outpatient clinic before hospital admission.
We performed emergency surgery. After cardiopul-
monary bypass (CPB) was initiated with ascending aorta
and right atrial cannulation, the ascending aorta was
cross-clamped and aortotomy was done at 2 cm distal to
the saphenous vein graft anastomosis. All leaflets of the
CEP were sclerotic [Figure 1] and the left and non-
coronary cusps were fused. We excised the leaflets to
ensure full inspection of the aortic annulus because the
stents of the valve strongly adhered to the aortic wall
and then removed the remnant rigid structures of the
CEP. No abscess or necrosis was found around the pros-
thesis. A new 19 mm Epic Supra bioprosthesis (St. JudeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Explanted Carpentier-Edwards Perimount valve.
Thickening and sclerosis are observed in the incised cusps.
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annular fashion using 14 mattress sutures with spaghetti
after the intimal defect at the annulus of the left coron-
ary cusp was repaired with autologous pericardium. The
patient was weaned from CPB without difficulty under
continuous administration of low dose cathecholamine.
The post-operative course was uneventful. UCG showed
a maximum pressure gradient of 27 mm Hg and a
slightly reduced FS of 26% at 10 days after the re-
operation but the FS had recovered to 35% by 16 days
after the re-operation.
Histopathologic examination demonstrated moderate
to severe calcification and hyalinization on the explanted
valves. X-ray examination showed acinar calcification in
the cusps of the explanted valves [Figure 2]. There was
infiltration of neutrophils, histiocytes and lymphocytes.
Arterial blood gas analysis showed a plasma free Ca2+ ofFigure 2 Acinar and linear calcifications are found in the cusps
by X-ray examination.4.0-4.4 mg/dl, which was just below the normal value of
4.8-5.4 mg/dl before and after surgery.
Discussion
This report describes a case of early cuspal calcifications
of a bioprosthetic valve in an elderly woman who had
been taking alfacalcidol for 3 years for osteoporosis after
the initial valve replacement. We could not find any
reports of early prosthetic valve calcification in patients
taking vitamin D supplementation, whereas it has been
reported that administration of vitamin D caused the de-
velopment of aortic stenosis in rabbits [4]. Calcification
in bioprosthetic valves is accelerated by younger recipi-
ent age, glutaraldehyde fixation, high mechanical stress
and chronic kidney disease including dialysis [5,6]. In a
recent paper evaluating 25 years of experience with the
CEP (Model 6900) in the mitral position, structural valve
deterioration occurred more frequently in recipients
under 60 years of age compared to those over 60 and
was unrelated to the etiology of the native valve disease
[7]. The patient in this case report had received initial
valve replacement at the age of 71 and did not have
chronic kidney disease or other risks for early valve cal-
cification. This case suggests that vitamin D may acceler-
ate calcification of bioprosthetic valves. Vitamin D is
sometimes used for treatment of osteoporosis, and per-
haps should be used carefully after bioprosthetic valve
replacement because the age of patients at valve replace-
ment has increased recently, so that more patients who
receive bioprosthetic valves also require treatment for
osteoporosis due to increased age.
The mechanism of calcification on bioprosthetic valves
is not completely understood. Calcification occurs within
nonviable connective tissue cells which are treated by glu-
taraldehyde through a reaction of calcium-containing
extracellular fluid with membrane-associated phosphorus.
Glutaraldehyde-treated cells are unable to pump out cal-
cium from the cytoplasm and inter-cellular structures,
which are high in phosphorus and can bind calcium,
whereas the membranes of normal healthy cells pump cal-
cium out to maintain a level 1000 to 10000 times lower
than plasma or extracellular calcium concentrations [2].
Higher extracellular calcium concentrations may acceler-
ate bioprosthetic valve calcification. Serum calcium con-
centration in the present case was 9.1 ± 0.7 mg/dl, within
the normal range of 8.0 to 10.2 mg/dl, although the pa-
tient had been taking 1 μg/day of alfacalcidol for 3 years.
Plasma free calcium ion was 4.0-4.4 mg/dl in arterial
blood gas analysis before and after the re-AVR. High
calcium concentration did not seem to be directly related
to early calcification in the present case. Liao K et al.
reported that the administration of diphenylhydantoin, a
vitamin D antagonist, for 45 days inhibited calcification of
bovine pericardium implants treated with glutaraldehyde
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osteocalcin synthesis and it also activates calcium-binding
proteins and increases calcium absorption [8]. Vitamin D
might have directly accelerated prosthetic valvular calcifica-
tion through osteocalcin without increasing serum calcium
concentration in the present case. It was also recently
reported that osteoporosis treatment with bisphosphonates
or calcitonin or selective estrogen receptor modulators
inhibited progression of aortic stenosis [9]. These authors
speculate that the inhibition was due to changes in vitamin
D and parathyroid hormone levels and that osteopontin
mediated the effect of bisphosphonates on calcification of
the aortic valve. Further studies would be warranted to
understand the effects of regulators in bone metabolism,
which include vitamin D and its analogues, on calcification
of bioprosthetic valves.
Conclusion
We report early bioprosthetic valve calcification in a pa-
tient taking alfacalcidol supplementation, although serum
calcium concentrations in the patient had been within
normal limits. This case suggests the possibility that vita-
min D may accelerate calcification of bioprosthetic valves.
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